USA - NYSE:PKI - US7140461093 - Common Stock
The current stock price of PKI is 115.24 USD. In the past month the price decreased by -15.23%. In the past year, price decreased by -21.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.17 | 212.89B | ||
| DHR | DANAHER CORP | 28.67 | 158.25B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 144.36 | 47.09B | ||
| A | AGILENT TECHNOLOGIES INC | 26.9 | 41.56B | ||
| IQV | IQVIA HOLDINGS INC | 18.96 | 36.96B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.71 | 29.25B | ||
| WAT | WATERS CORP | 28.76 | 20.94B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.63 | 20.65B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.71 | 16.76B | ||
| TEM | TEMPUS AI INC | N/A | 15.91B | ||
| ILMN | ILLUMINA INC | 24.12 | 15.42B | ||
| ICLR | ICON PLC | 13.8 | 14.16B |
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. Its products and services for Discovery & Analytical Solutions applications include The Opera Phenix Plus high-content screening system, The Operetta CLS high-content analysis system, The MuviCyte live-cell imaging system, and The Signals Image Artist. Its products and services for Diagnostics applications include The DELFIA Xpress screening platform, The Specimen Gate informatics data management solution and The DELFIA Xpress sFlt-1 kit.
PERKINELMER INC
940 Winter Street
Waltham MASSACHUSETTS 02451 US
CEO: Prahlad Singh
Employees: 16700
Phone: 17816635776.0
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. Its products and services for Discovery & Analytical Solutions applications include The Opera Phenix Plus high-content screening system, The Operetta CLS high-content analysis system, The MuviCyte live-cell imaging system, and The Signals Image Artist. Its products and services for Diagnostics applications include The DELFIA Xpress screening platform, The Specimen Gate informatics data management solution and The DELFIA Xpress sFlt-1 kit.
The current stock price of PKI is 115.24 USD. The price decreased by -0.91% in the last trading session.
PKI does not pay a dividend.
PKI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PKI.
PERKINELMER INC (PKI) will report earnings on 2023-07-31, before the market open.
ChartMill assigns a fundamental rating of 4 / 10 to PKI. While PKI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PKI reported a non-GAAP Earnings per Share(EPS) of 7.94. The EPS decreased by -30.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.32% | ||
| ROA | 5.28% | ||
| ROE | 10.11% | ||
| Debt/Equity | 0.53 |
20 analysts have analysed PKI and the average price target is 159.39 USD. This implies a price increase of 38.31% is expected in the next year compared to the current price of 115.24.
For the next year, analysts expect an EPS growth of -34.36% and a revenue growth -31.32% for PKI